secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPLASH BEVERAGE GROUP, INC. (SBEV)
CIK:        0001553788
Form:       8-K
Filed at:   2026-08-05T12:35:42+00:00
Accession:  0001731122-26-001020
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Splash Beverage Group partners with Lupvindol Biosciences to advance CannEpil through FDA veterinary pathway
--------------------------------------------------------------------------------

- Collaboration targets companion-animal oncology and chronic pain management; canine applications are initial focus.
- Lupvindol CEO Hunter Land, Ph.D., led development of first FDA-approved plant-derived cannabinoid medicine Epidiolex.
- Global veterinary pain-management market valued at $2.6B in 2024, projected to reach $3.8B by 2030.
- Splash retains ownership of data, IP, and commercialization rights; provides milestone-based funding.
- Program aims for FDA Conditional Approval under Section 571 of FD&C Act; no assurance of approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553788/000173112226001020/0001731122-26-001020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553788/000173112226001020/e7828_8k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-26-001020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer